Skystar Bio-pharmaceutical Co. (fka SKBI)

[236T568]

How long before the SEC suspends trading in SKBI stock and files formal fraud charges?

[236T568]

the excuse that some evil short seller bribed an employee to provide false bank statements to the auditors and that this also caused all of the cash, $16 million, to be missing from the SKBI bank account has got to be one of the funniest that I have seen in years

So there is nothing you can teach me.

[tbirdman]

Save your breath, he will defend it for defending it's sake. We all know where this is headed. And thanks for your contributions to i-hub btw. I have made some good money off your posts.

[RealDutch]

a "false bank statement" is just that, a false bank statement, which as you are going to see, will lead to fraud charges

Fraud charges against who or what? They haven't even reported the numbers. A little detail you forgot about, I guess.

say, tell us again about your claim of how the Evil Naked Short Sellers from Mars have been involved in bribing the low level SKBI employees.

Oh, that's wonderful. Very impressive

[236T568]

seriously?

tell us again about your claim that the Evil Naked Short Sellers from Mars have been bribing SKBI employees to provide fraudulent financials to the auditors and this has caused $16 million cash to appear missing from the SKBI bank accounts

it appears that there is a lot of learning left here

So there is nothing you can teach me.

[RealDutch]

so are you saying that failure to file the 2014 10k, failure to file the 2015 Q1 10Q, failure to file the 2015 Q2 10Q, providing fraudulent bank statements to the auditor, $24 million in A/R that were never collected and failure to find $16 million in cash are minor?

Look, I was the one who said that SKBI was overvalued when people were willing to pay $6 or $8 for the stock. The company was having problems with getting licenses and account receivables back then. It was all in the SEC filings. Perhaps I didn't talk about it on this message board, but elsewhere. So there is nothing you can teach me. Besides, it's too late now, isn't it. You should have pointed it out 6 months ago.

[236T568]

huh?

a "false bank statement" is just that, a false bank statement, which as you are going to see, will lead to fraud charges


if you read the SEC filings you would see that $16 million in cash, all of the cash that the company had, is somehow missing

this is going to end up bad

real bad




say, tell us again about your claim of how the Evil Naked Short Sellers from Mars have been involved in bribing the low level SKBI employees.

where do you come up with these things?

Quote:
some accountant made an error?


My point is simply, mistakes are made all the time. Deliberate or not, it's the auditor's job to audit it and have the company rectify it.

Now, perhaps a group of short sellers bribed a low level employee to falsify the numbers. Who really knows what goes on behind the scenes. Should the company and thousands of shareholders pay the price for that? Should the company be delisted because of that? No, not when the company handled it properly, which means firing the employee and proscecute him. That is why the auditor didn't resign, and believe me, this one is strict.

But all you guys can do is scream "fraud". Well, it is rather obvious that you are short the stock. Me, I have no position.

I'm not aware that $16M is missing. But what I said applies here too. Don't jump to conclusions.

[236T568]

huh?

so are you saying that failure to file the 2014 10k, failure to file the 2015 Q1 10Q, failure to file the 2015 Q2 10Q, providing fraudulent bank statements to the auditor, $24 million in A/R that were never collected and failure to find $16 million in cash are minor?

I never suggested that SKBI is a good investment. But the way Nasdaq handles some of these cases, they simply bend the rules whenever they can. At one point they delisted a company because they didn't have a viable business, according to Nasdaq. So now we have an exchange operator deciding which companies have a viable business. They sure as hell went outside the rules when they delisted ABAT. And then there is the case of that cleantech company where the SEC had to revert their delisting decision, after they delisted the company.

[236T568]

A review of SKBI's financials that were filed shows that the $16 million cash adjustment completely wipes out all unrestricted cash for the company

One other bone to pick I have with SKBI is they diluted last year...shortly after saying they had enough cash. Just shady business imo, but we will soon see how it all plays out.

[RealDutch]

some accountant made an error?

My point is simply, mistakes are made all the time. Deliberate or not, it's the auditor's job to audit it and have the company rectify it.

Now, perhaps a group of short sellers bribed a low level employee to falsify the numbers. Who really knows what goes on behind the scenes. Should the company and thousands of shareholders pay the price for that? Should the company be delisted because of that? No, not when the company handled it properly, which means firing the employee and proscecute him. That is why the auditor didn't resign, and believe me, this one is strict.

But all you guys can do is scream "fraud". Well, it is rather obvious that you are short the stock. Me, I have no position.

I'm not aware that $16M is missing. But what I said applies here too. Don't jump to conclusions.

[236T568]

huh?

some accountant made an error?

providing FALSE bank statements to the auditor would not be consider just an accountant's error

this is fraud!

say, can you tell us where the missing $16 million cash is?

Regarding "disclosure of material information", Nasdaq twists this any way they want to, it's a freaking joke. Nasdaq is a freaking joke. Asif every company discloses the fact that some accountant made an error. The auditor noticed it (what they were hired to do) and they fixed it. Job done.

[236T568]

and importantly, in addition to the bank fraud, the increase in Accounts receivable of $24 million that were not collected (equal to 2 quarters worth of revenues), there appears to be $16 million in cash missing, according to SKBI's SEC filings

[tbirdman]

Hmmm...something leak? Bid jumped all of a sudden.

[RealDutch]

Whether or not SIXD (or cleantech) is a fraud (or turns out to be a fraud) is completely irrelevant. Nasdaq should stick to the rules and not abuse the power that was given to them. I do think you get my point. Asif Nasdaq is going to tell the SEC now, "na na, see, we were right". Well, they would do that too, I guess.
And it's going to be no different with SKBI. They don't have a chance!

[tbirdman]

Yes sir, well aware of that. Clean Tech is now SIXD (reverse merger) . Those involved with this co. don't get any more dirty (including Benjamin Wei & his New York Global Group). I remember being intrigued with that one, but waving the racist flag was a desperate attempt at salvaging assets to build another scam. Let's get back on topic please (SKBI).

[RealDutch]

It was CleanTech I was referring to.

In Rare Move, SEC Reverses Nasdaq's Delisting Of Chinese Company
http://www.forbes.com/sites/davidyin/2013/08/02/in-rare-move-sec-reverses-nasdaqs-delisting-of-chinese-company/

In a landmark decision last month, the U.S. Securities and Exchange Commission slapped down Nasdaq and reversed its decision to delist a Chinese alternative energy company. The SEC determined that CleanTech Innovations had not intentionally withheld crucial information from Nasdaq.

Which was basically more evidence (to me) that Nasdaq are a bunch of racists.

[tbirdman]

Bad example, lol. I get where you are coming from, but "that cleantech company" (now SIXD) turned out to be a massive fraud (currently halted).

[RealDutch]

I never suggested that SKBI is a good investment. But the way Nasdaq handles some of these cases, they simply bend the rules whenever they can. At one point they delisted a company because they didn't have a viable business, according to Nasdaq. So now we have an exchange operator deciding which companies have a viable business. They sure as hell went outside the rules when they delisted ABAT. And then there is the case of that cleantech company where the SEC had to revert their delisting decision, after they delisted the company.

[tbirdman]

Asif every company discloses the fact that some accountant made an error.

Bank fraud is much different than some minor accounting error.

You really have to lean on the cautious side here. Only glimmer of hope is it appears the auditor has not resigned yet, and they have an activist shareholder that is probably kicking and screaming right now.

One other bone to pick I have with SKBI is they diluted last year...shortly after saying they had enough cash. Just shady business imo, but we will soon see how it all plays out.

[RealDutch]

Regarding "disclosure of material information", Nasdaq twists this any way they want to, it's a freaking joke. Nasdaq is a freaking joke. Asif every company discloses the fact that some accountant made an error. The auditor noticed it (what they were hired to do) and they fixed it. Job done.

[tbirdman]

$SKBI - here are the issues outstanding:



https://listingcenter.nasdaq.com/NonCompliantCompanyList.aspx

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001144204-15-060610%2Etxt&FilePath=%5C2015%5C10%5C23%5C&CoName=SKYSTAR+BIO-PHARMACEUTICAL+CO&FormType=8-K&RcvdDate=10%2F23%2F2015&pdf=

There is bank fraud involved.

There is also the issue of ballooning accounts receivable as noted in the NT-10Q (classic Chinese scam tactic).



http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001144204-15-049937%2Etxt&FilePath=%5C2015%5C08%5C14%5C&CoName=SKYSTAR+BIO-PHARMACEUTICAL+CO&FormType=NT+10-Q&RcvdDate=8%2F14%2F2015&pdf=

So the company's financials are deteriorating, bank fraud has surfaced, and they are delinquent in multiple filings. And China. Nice.

[236T568]

yes, still trading

b/a now 1.00/1.05

you would think that if request for hearing letter was sent to NASDAQ by SKBI, that the company would let the public know about this material event

Odd nothing filed yet...on the other hand looks like $1.00 falls soon.

[tbirdman]

Odd nothing filed yet...on the other hand looks like $1.00 falls soon.

[236T568]

I didn't include that one because it was posted this morning/late last night

[tbirdman]

Looks like more are being posted, another one up now...


Escalera Resources Co. ESCR Company Choice/Regulatory Matter Pending Suspended 10/29/2015

[236T568]

3 new tickers added that were suspended for 10/29/15, SKBI not added yet:


https://listingcenter.nasdaq.com/IssuersPendingSuspensionDelisting.aspx

ATRM Holdings, Inc. ATRM Regulatory/Non Compliance Suspended 10/29/2015

ContraFect Corporation CFRXZ Expiration Suspended 10/29/2015 10/28/2015

LookSmart, Ltd. LOOK Acquisition/Merger Suspended 10/29/2015 10/28/2015

[236T568]

Also, nothing filed with the SEC

http://www.sec.gov/cgi-bin/browse-edgar?CIK=skbi&owner=exclude&action=getcompany&Find=Search


and no new press releases by SKBI

[236T568]

not sure but could be midnight EST

[tbirdman]

Thanks, do you know what time that list is updated?

[236T568]

https://listingcenter.nasdaq.com/IssuersPendingSuspensionDelisting.aspx

[tbirdman]

Hmm....will see soon enough

[236T568]

"This service has expired. Please contact Issuer Direct at 919-481-4000 ext. 111 to renew service."


from the SKBI corporate website for the pages titled:


NEWS

Stock Information

SEC filings


http://www.skystarbio-pharmaceutical.com/news.php

[tbirdman]

Wonder if he's still holding the bag?

[tbirdman]

[236T568]

Oops, time is up...see red below



http://www.sec.gov/Archives/edgar/data/1076939/000114420415060610/v422717_ex99-1.htm

SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION LETTER



Xi’an, China, October 23, 2015 – Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on October 20, 2015 it received a letter from NASDAQ Stock Market indicating that that Skystar failed to comply with Nasdaq’s filing requirement set forth in Listing Rule 5250(c)(1) (the “Rule”) because it failed to file its Form 10-K for the fiscal year ended December 31, 2014, and Forms 10-Q for the periods ended March 31, and June 30, 2015, respectively (together, the “Delinquent Reports”).



Based on its review of the materials submitted by Skystar (together, the “Submissions”), Nasdaq’s staff granted Skystar an exception until October 12, 2015, to file the Delinquent Reports and thereby regain compliance with the Rule (the “Exception”). The notification letter indicated that because the Company has not filed the Delinquent Reports and does not meet the terms of the Exception.



Nasdaq also notified Skystar of two additional, and separate, bases for delisting under Listing Rule 5250(b)(1) (failure to disclose material non-public information) and Listing Rule 5101 (public interest concerns). The information to which Nasdaq referred was the conduct by Skystar’s audit committee of an internal investigation into certain allegations, raised by Skystar’s auditors, that the auditors had been presented by Skystar personnel with false bank documents relating to one bank account. The public interest concerns arise from the audit committee’s determination that a low level employee had falsified bank documents relating to one bank account, which were then provided to the auditors by other Skystar personnel who were unaware of the falsehood. The employee who falsified the document is no longer with Skystar. After the audit committee concluded its investigation, the Company’s external auditors have resumed their audit of Skystar’s financial statements for the year ended December 31, 2014. Nasdaq’s notice indicated that all of the foregoing constituted a basis for delisting by Nasdaq.



NASDAQ Delisting Action



Skystar intends to request a review of the delisting determination by NASDAQ’s Listing Qualifications Panel. The hearing is generally scheduled approximately 30-45 days after the date of the hearing request. Unless Skystar files a request for a hearing, Skystar’s common stock will be suspended from trading on October 29, 2015. A request for a hearing regarding a delinquent filing will stay the suspension for a period of 15 days from the date of the request. Pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, when Skystar requests a hearing, Skystar will request a stay of the suspension, pending the hearing. A Panel will review the request for an extended stay and notify Skystar of its conclusion as soon as is practicable but in any event no later than 15 calendar days following the deadline to request the hearing. Skystar will inform the public of the conclusion of the Panel and subsequent hearing date.

[tbirdman]

Nice spamming, no thanks.

[tbirdman]

Lot of people WATCHING this one...they come current on filings, risk of delisting evaporates and we see 20-40% gain in one day. Until then we wade in the muck.

Chart finally bottomed out...wonder what John Gregory is thinking about now. If he hadn't upped his stake I wouldn't be here.

[stocktrademan]

$SKBI recent news/filings

bullish
bottom bounce

## source: finance.yahoo.com

Fri, 22 May 2015 21:04:04 GMT ~ Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Non-Compliance Letter Due to Delay in Filing Form 10-Q

[at noodls] - XI'AN, CHINA--(Marketwired - May 22, 2015) - Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, ...

read full: http://www.noodls.com/view/1021A78145D10CBC4E43936718C4480A2EB21F71
*********************************************************

Fri, 22 May 2015 21:02:18 GMT ~ SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule


read full: http://biz.yahoo.com/e/150522/skbi8-k.html
*********************************************************

Fri, 22 May 2015 21:00:00 GMT ~ Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Non-Compliance Letter Due to Delay in Filing Form 10-Q

[Marketwired] - Skystar Bio-Pharmaceutical Company , a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification ...

read full: http://finance.yahoo.com/news/skystar-bio-pharmaceutical-company-announces-210000766.html
*********************************************************

Wed, 15 Apr 2015 21:22:08 GMT ~ SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule


read full: http://biz.yahoo.com/e/150415/skbi8-k.html
*********************************************************

Wed, 15 Apr 2015 21:00:00 GMT ~ Skystar Bio-Pharmaceutical Company Announces Receipt of NASDAQ Non-Compliance Letter Due to Delay in Filing Form 10-K

[Marketwired] - Skystar Bio-Pharmaceutical Company , a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that the Company received a notification ...

read full: http://finance.yahoo.com/news/skystar-bio-pharmaceutical-company-announces-210000382.html
*********************************************************

$SKBI charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$SKBI company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/SKBI/company-info
Ticker: $SKBI
OTC Market Place: Not Available
CIK code: 0001076939
Company name: Skystar Bio-Pharmaceutical Company
Incorporated In: NV, USA


$SKBI share structure

## source: otcmarkets.com

Market Value: $28,178,092 a/o Jun 12, 2015
Shares Outstanding: 8,696,942 a/o Jan 31, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$SKBI extra dd links

Company name: Skystar Bio-Pharmaceutical Company
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SKBI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SKBI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SKBI+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SKBI/news - http://finance.yahoo.com/q/h?s=SKBI+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SKBI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SKBI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SKBI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SKBI
DTCC (dtcc.com): http://search2.dtcc.com/?q=Skystar+Bio-Pharmaceutical+Company&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Skystar+Bio-Pharmaceutical+Company
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Skystar+Bio-Pharmaceutical+Company&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SKBI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001076939&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SKBI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SKBI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SKBI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SKBI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SKBI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SKBI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SKBI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SKBI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SKBI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SKBI+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SKBI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SKBI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SKBI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SKBI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SKBI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SKBI/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SKBI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SKBI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SKBI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SKBI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SKBI



$SKBI DD Notes ~ http://www.ddnotesmaker.com/SKBI

[surfer44]

Sorry I picked an IHub name similar to yours. Someone made me aware of that awhile back and asked about it. I wasn't aware of your name when I picked mine.

[surfer44]

Interesting SKBI youtube. Begins at 5:00

[martin79]

Gregory just bought $300,000 worth of SKBI. Great company and overdue for a nice run

http://archive.fast-edgar.com/20141229/AS22Q22CZZ22S9KU229P2Z322JG3IC22Z262

[stocktrademan]

Skystar Bio-Pharmaceutical Company [$SKBI] due diligence

bullish

$SKBI

DD Notes ~ http://www.ddnotesmaker.com/SKBI

##### recent news/filings ~ source: finance.yahoo.com

Fri, 23 May 2014 17:04:23 GMT ~ SKYSTAR BIO-PHARMACEUTICAL CO Financials
read full: http://finance.yahoo.com/q/is?s=skbi
*********************************************************

Fri, 16 May 2014 14:12:04 GMT ~ Skystar Bio-Pharmaceutical's (SKBI) CEO Weibing Lu on Q1 2014 Results - Earnings Call Transcript
[at Seeking Alpha] - Scott Cramer Hi, Chris. And thank you so much. Good morning everyone and welcome to Skystar's first earnings call for fiscal 2014. I will be delivering prepared comments on behalf of the company. And as ...
read full: http://seekingalpha.com/article/2222563-skystar-bio-pharmaceuticals-skbi-ceo-weibing-lu-on-q1-2014-results-earnings-call-transcript?source=yahoo
*********************************************************

Thu, 15 May 2014 21:00:21 GMT ~ Skystar Bio-Pharmaceutical Reports First Quarter Fiscal Year 2014 Financial Results
[Marketwired] - Skystar Bio-Pharmaceutical Company , a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited first quarter fiscal year ...
read full: http://finance.yahoo.com/news/skystar-bio-pharmaceutical-reports-first-210021111.html
*********************************************************

Thu, 15 May 2014 20:30:37 GMT ~ SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/140515/skbi10-q.html
*********************************************************

Thu, 15 May 2014 13:00:00 GMT ~ Skystar Bio-Pharmaceutical to File Financial Results for First Quarter of Fiscal 2014 on Thursday, May 15
[Marketwired] - Skystar Bio-Pharmaceutical Company , a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the first quarter ...
read full: http://finance.yahoo.com/news/skystar-bio-pharmaceutical-file-financial-130000060.html
*********************************************************

##### chart ~ source: stockcharts.com



##### chart ~ source: eoddata.com



##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/SKBI/company-info
Ticker: $SKBI
OTC Market Place: Not Available
CIK code: 0001076939
Company name: Skystar Bio-Pharmaceutical Company
Incorporated In: NV, USA

##### extra dd links

Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001076939&owner=exclude&count=40
Latest filings: http://www.otcmarkets.com/stock/SKBI/filings
Latest financials: http://www.otcmarkets.com/stock/SKBI/financials
Latest news: http://www.otcmarkets.com/stock/SKBI/news - http://finance.yahoo.com/q/h?s=SKBI+Headlines

Major holdings: http://data.cnbc.com/quotes/SKBI/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=SKBI+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/SKBI.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=SKBI

RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=SKBI&search=search

DTCC: http://search2.dtcc.com/?q=Skystar+Bio-Pharmaceutical+Company&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Skystar+Bio-Pharmaceutical+Company
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Skystar+Bio-Pharmaceutical+Company&x=0&y=0

Short Sales: http://www.otcmarkets.com/stock/SKBI/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/SKBI/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/SKBI/research
Historical Prices: http://finance.yahoo.com/q/hp?s=SKBI+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=SKBI+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=SKBI+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=SKBI+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=SKBI+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=SKBI+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=SKBI
Balance Sheet: http://finance.yahoo.com/q/bs?s=SKBI
Cash Flow: http://finance.yahoo.com/q/cf?s=SKBI+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/SKBI
Bloomberg: http://www.bloomberg.com/quote/SKBI:US
Morningstar: http://quotes.morningstar.com/stock/s?t=SKBI
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SKBI
Barchart: http://www.barchart.com/quotes/stocks/SKBI
OTC Short Report: http://otcshortreport.com/index.php?index=SKBI
Investopedia: http://www.investopedia.com/markets/stocks/SKBI/?wa=0

http://www.pennystocktweets.com/stocks/profile/SKBI

##### last known share structure ~ source: otcmarkets.com

Market Value: $54,070,128 a/o Jun 26, 2014
Shares Outstanding: 7,604,800 a/o Aug 12, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

##### business description ~ source: otcmarkets.com



DD Notes ~ http://www.ddnotesmaker.com/SKBI
xlfv

[easymoney123]

Louis Navalier's site has a strong buy rating, seems like someone thinks he will do an article soon. This big pullback is a gift itself with sellers not understanding the valuation on this stock. Fundamental highlights: $13.50 book value, EPS $1.50 this year, more growth projected next year. Currently company is not running on full capacity, during the CC transcript, at full capacity could do $100 million or more 2014 sales...currently company is on track do to $45 million.

[easymoney123]

BOOM! Its go time Monday.

[easymoney123]

BOOM! Its go time Monday.

[easymoney123]

SKBI earnings release today afterhours, lets see if its good.

[surf1944]

http://www.ir-site.com/skystar/sec.asp

[surf1944]

http://www.ir-site.com/skystar/press.asp

[surf1944]

Skystar Bio-Pharmaceutical Announces Results for Third Quarter Fiscal Year 2012
Veterinary Medication Facility Resumes Production and Distribution; Veterinary Vaccine Facility Receives Initial GMP Certification
MarketwirePress Release: Skystar – Thu, Nov 15, 2012 5:30 AM EST

XI'AN, CHINA--(Marketwire - Nov 15, 2012) - Skystar Bio-Pharmaceutical Company ( NASDAQ : SKBI ) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited third quarter fiscal year 2012 earnings, for the period ended September 30, 2012.

Third Quarter 2012 Highlights

Revenue decrease 57% YoY to $8.9 million
Veterinary vaccines totaled $1.0 million, up 19% YoY
Veterinary medicines totaled $1.8 million, down 86% YoY
Feed additives totaled $1.2 million, up 13% YoY
Probiotics products totaled $4.9 million, down 18% YoY
Gross margin of 59% for the third quarter of fiscal 2011 as compared to 52% in the year ago period
GAAP net income declined 65% to $2.7 million or $0.36 per fully diluted share, compared with net income of $7.7 million or $1.08 per fully diluted share in the year ago period
Fiscal 2012 top line revenue guidance range revised from $33 million to $38 million reflecting inactivity of the veterinary medications facility due to timing of its GMP re-certification process.

Nine Month 2012 Highlights

Net revenue declined 31% YoY to $25.7 million
Gross profit of $14.7 million for the nine months of fiscal 2012 as compared to $18.9 million in the year ago period
GAAP net income $6.3 million, compared with GAAP net income of $11.2 million in the year ago period

Mr. Weibing Lu, Skystar Bio-Pharmaceutical's Chairman and Chief Executive Officer, commented, "Skystar has made significant strides in moving its infrastructure forward in support of manufacturing capacity for the Company's veterinary medication and vaccine lines providing a solid outlook in the medium and long term.

"Skystar has resumed production and distribution of its primary veterinary medicine following GMP recertification by the Ministry of Agriculture. In addition, Skystar's animal and aquaculture vaccine production facility passed initial GMP certification, and, when it operates and reaches its full production levels, is expected to generate at minimum $15 million in annual sales.

"Once operational, the much anticipated vaccine facility will allow Skystar to mass produce vaccines currently produced by hand in large quality controlled batches. Both the certification of the veterinary medicine and vaccine plants are significant milestones for Skystar and are vital in supporting the Company's growth in upcoming years."

Mr. Lu concluded, "In terms of Skystar's performance for the 3rd quarter of 2012, it is noteworthy that, in spite of China's 'soft' economic performance which is partly attributable to fiscal policies designed to control inflation, Skystar has been able to maintain and, at times, marginally increase sales pricing for its products. With this in mind, Skystar's 3rd quarter revenue and bottom line largely reflect a revenue drop in its veterinary medication business in the 3rd quarter, which accounts for nearly 60% of Skystar's revenues in any given period. This is a short term effect related to the closure of Skystar's veterinary medication facility during the pendency of the GMP recertification process. Now that Skystar has resumed production at this facility, Skystar can continue its commitment to maintaining bottom line profitability in its organic business in order to fund growth and expansion initiatives internally for years to come."

Forecast
With the loss of revenue from the veterinary medication plant for all of the third quarter, Skystar's seasonally strongest quarter, the Company is recasting guidance to be in the range of $33 million to $38 million for fiscal 2012.

Financial Summary
Revenues for third quarter 2012, decreased 57% to $8.9 million as compared to $20.9 million in the year ago period.

Gross profit third quarter 2012 was roughly $5.3 million, down 52% from third quarter 2011.

Gross margin for the period was higher at 59% compared to 52% in the year ago period, due to the change in available product mix for sale.

Total operating expenses for third quarter 2012 was $1.6 million, or 18% of total revenue, compared with $1.9 million or 9% of total revenue in the year ago period.

Research and development costs totaled roughly $200,000 for the period, as compared to roughly $91,000 for the three months ended September 30, 2011, an increase of 118%.

Selling expenses totaled $690,000 for third quarter 2012 as compared to $1.2 million for the comparable year ago period this was a decrease of roughly $480,000 or 41%.

General and administrative expenses totaled $730,000 in the third quarter of 2012 as compared to $602,000 for the year ago period, an increase of $128,000 or 21%.

Operating income decreased 59% year over year and was $3.6 million in the third quarter of fiscal 2012 as compared to $9.0 million in the year ago period, operating margin remained level at 41% as compared to 43% from the year ago period.

Net income for the third quarter of 2012 was $2.7 million, or $0.36 per fully diluted share. This compares to net income of $7.7 million or $1.08 per fully diluted share in the same quarter of 2011.

As of September 30, 2012, Skystar had approximately $2.7 million in cash and current assets of $73 million and current liabilities of $20 million.

Conference Call & Webcast Information
The Company will host a conference call on Thursday, November 15, 2012 to discuss the quarter. Skystar's conference call will begin promptly at 7:45 a.m. ET to discuss third quarter financial results and operational performance. Mr. Weibing Lu, Skystar's chairman and chief executive officer, will host the call, which will be webcast live.

Webcast
The webcast will be made available on the investor relations section of the Skystar corporate website at http://www.investorcalendar.com/IC/CEPage.asp?ID=170249.

http://finance.yahoo.com/news/skystar-bio-pharmaceutical-announces-results-103000821.html

[surf1944]

Management Comments
Mr. Weibing Lu, Skystar Bio-Pharmaceutical's chairman and chief executive officer, commented, "Skystar made significant progress in the second quarter of fiscal 2012 in its evolution to scale up its business. During the period, Skystar has been able to maintain fiscal profitability, control raw materials costs and operating expenses while moving forward with efforts to modernize and automate manufacturing of its veterinary vaccine, medication, probiotic and feed additives lines.

"In order to maintain revenue and profit in a 'GMP certification' year for several of Skystar's production facilities, Management has ramped sales and marketing for other parts of the business and introduced various customer concession and retention programs to compensate for a reduced supply of veterinary medicine products and not have to reduce the price of products to customers.

"As previously announced on June 26, 2012, China's Ministry of Agriculture (MOA) experts' physically inspected the Company's Huxian veterinary medicine manufacturing plant and published its recommendation to renew Skystar's GMP certificate, valid for a period of five years. While the Company awaits post-inspection procedures from the MOA, the veterinary medicine plant in Huxian remains closed. Skystar anticipates the renewed GMP certificate will be physically received in the third quarter of 2012. During this time, the Company successfully shifted its sales strategy temporarily to other product lines, mainly probiotics and feed additives. The goal of this exercise was not only to maintain revenue guidance but to take the opportunity to further inroads in expanding the sales footprint of its probiotics line whose record sales doubled as compared to the same period a year ago.

"Operationally, the Compared pared back research and development activities, primarily moving forward with projects that were paid for already in previous years. As the GMP recertification at Huxian's veterinary medicine facility heads closer towards full production the Company anticipates increasing efforts and investment in research and development at that juncture.

"Management is excited to share its results at the half year mark. Skystar has been able to successfully implement its operational strategy as it moves towards the most profitable half of the fiscal year. We believe that the course management has plotted will position Skystar to make forecasted fiscal guidance for 2012 and to position the Company for revamped growth in fiscal 2013," concluded Mr. Lu.

http://finance.yahoo.com/news/skystar-bio-pharmaceutical-reports-second-202000649.html